A Phase I, Single Center, Double-blind Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Intravenous AZD9742 After Administration of Multiple Ascending Doses for 14 Days in Healthy Male and Female Subjects.
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2016
At a glance
- Drugs AZD 9742 (Primary)
- Indications Methicillin-resistant Staphylococcus aureus infections
- Focus Adverse reactions
- 05 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2010 Planned end date changed from 1 May 2010 to 1 Aug 2010 as reported by ClinicalTrials.gov.
- 19 Feb 2010 New trial record